What Medications to Avoid with ADOA (Optic Atrophy)?
At a Glance
People with Autosomal Dominant Optic Atrophy (ADOA) should avoid medications known as mitochondrial toxins, such as the antibiotics ethambutol and linezolid. These drugs can overwhelm already vulnerable optic nerve cells and rapidly accelerate permanent vision loss.
In this answer
3 sections
If you have Autosomal Dominant Optic Atrophy (ADOA), there are specific medications you should avoid or use only with extreme caution under close medical supervision. The most notable of these are known as “mitochondrial toxins,” which include certain antibiotics like ethambutol and linezolid. Taking these medications can exacerbate your underlying condition and accelerate vision loss [1][2].
It is crucial to inform every doctor, specialist, and pharmacist you see about your ADOA diagnosis before starting any new prescription. However, please be reassured: the vast majority of routine, everyday medications (like ibuprofen, acetaminophen, standard antibiotics for minor infections, and routine eye drops) are perfectly safe. The risk is generally limited to specific classes of drugs that directly impact cellular energy.
Why Are Certain Medications Dangerous for ADOA?
To understand why some drugs are harmful, it helps to understand how ADOA affects your eyes. ADOA is typically caused by a mutation in the OPA1 gene, which leads to mitochondrial dysfunction [3][4]. Mitochondria are the microscopic “powerhouses” inside your cells that generate energy.
The cells in your optic nerve—called retinal ganglion cells—require an enormous amount of continuous energy to transmit visual information from your eye to your brain. Because of this high energy demand, your optic nerve is extremely vulnerable to any disruptions in mitochondrial function [5][6].
Certain medications are classified as mitochondrial toxins because they interfere with the way mitochondria produce energy or replicate [7][8]. For a person with healthy mitochondria, the body can usually handle this temporary stress. However, if you have ADOA, your mitochondria are already compromised [4][9]. Introducing a mitochondrial toxin adds a “second hit” to your system. This exacerbates mitochondrial dysfunction, overwhelms the optic nerve cells, and can rapidly accelerate optic nerve damage [1][2].
(Note: When researching these medications on your own, you may often see them linked to Leber Hereditary Optic Neuropathy, or LHON. LHON is a different genetic eye disease, but because it shares the same underlying mechanism of mitochondrial dysfunction as ADOA, the strict medication precautions apply equally to both conditions [10][5].)
High-Risk Medications and Toxins to Watch Out For
While this is not an exhaustive list, the following substances pose a high risk of drug-induced toxic optic neuropathy:
- Ethambutol: An antibiotic primarily used to treat tuberculosis. It is strongly linked to triggering or severely worsening vision loss in patients with underlying hereditary optic neuropathies like ADOA [1][2].
- Linezolid: A strong antibiotic used for serious bacterial infections, such as MRSA. It is a known mitochondrial toxin that can cause drug-induced optic toxicity [11][7].
- Certain Antivirals: Some classes of antiviral medications, particularly nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV, can interfere with mitochondrial DNA replication and cause mitochondrial toxicity [12][13].
- Amiodarone: A medication used to treat irregular heart rhythms (arrhythmias). While it affects the eye through a slightly different pathway (cellular lipidosis and oxidative stress), it is strongly associated with oxidative damage to the optic nerve and drug-induced optic neuropathy [14].
- Lifestyle Toxins: Tobacco smoke and excessive, chronic alcohol consumption (e.g., heavy daily drinking or binge drinking) induce severe oxidative stress and act as potent mitochondrial stressors. They should be strictly avoided to protect your remaining vision [15].
How to Protect Yourself
You must be your own advocate when it comes to medication safety. Follow these steps to protect your vision:
- Always Disclose Your Diagnosis: Inform every healthcare provider and pharmacist that you have Autosomal Dominant Optic Atrophy.
- Use Specific Terminology: Explain to providers that you have a “hereditary mitochondrial optic neuropathy” and are at high risk for “toxic optic neuropathy.” This phrasing quickly alerts non-specialist doctors to the specific medical risks involved. You may even want to write this exact phrase, along with the high-risk drug list, on a medical card to keep in your wallet.
- Ask About Alternatives: If a doctor prescribes a new medication, ask, “Is this drug known to be a mitochondrial toxin or carry a risk of toxic optic neuropathy?” If the answer is yes, ask if there is a safer alternative available.
- Monitor Closely if Unavoidable: Sometimes, a high-risk medication is the only option to treat a life-threatening infection. If you absolutely must take one of these drugs, your medical team should monitor your vision very closely. This often involves regular eye exams using tools like Optical Coherence Tomography (OCT) to detect early signs of optic nerve stress before severe damage occurs [11][16].
- Report Sudden Changes Immediately: Because ADOA causes a very slow, gradual change in vision, you should be on the alert for anything fast. If you notice a sudden, rapid, or dramatic blurring of vision, an abrupt change in color perception, or a new, large blind spot shortly after starting a new medication, contact your doctor immediately. Discontinuing the offending medication is the primary way to halt drug-induced optic nerve damage [17].
Common questions in this guide
Why do I need to avoid certain medications if I have ADOA?
What specific antibiotics should I avoid with Autosomal Dominant Optic Atrophy?
Are over-the-counter painkillers safe to take with ADOA?
What should I do if I notice a sudden change in my vision after starting a new medication?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are any of my current prescription medications, including my heart medications or long-term treatments, considered mitochondrial toxins?
- 2.If I am ever hospitalized with a severe infection, how can we ensure that the infectious disease team knows to avoid drugs like linezolid or ethambutol?
- 3.Should we establish a baseline Optical Coherence Tomography (OCT) scan now, so we have something to compare against if I ever need to take a high-risk medication?
- 4.What over-the-counter medications or supplements are completely safe for me to use for everyday illnesses?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
Genetic Spectrum and Characteristics of Hereditary Optic Neuropathy in Taiwan.
Lin CW, Huang CW, Luo AC, et al.
Genes 2021; (12(9)) doi:10.3390/genes12091378.
PMID: 34573359 - 2
Electrodiagnostic tests of the visual pathway and applications in neuro-ophthalmology.
Calcagni A, Neveu MM, Jurkute N, Robson AG
Eye (London, England) 2024; (38(12)):2392-2405 doi:10.1038/s41433-024-03154-6.
PMID: 38862643 - 3
Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.
Kushnareva Y, Seong Y, Andreyev AY, et al.
Cell death & disease 2016; (7()):e2309 doi:10.1038/cddis.2016.160.
PMID: 27468686 - 4
Sustained intracellular calcium rise mediates neuronal mitophagy in models of autosomal dominant optic atrophy.
Zaninello M, Palikaras K, Sotiriou A, et al.
Cell death and differentiation 2022; (29(1)):167-177 doi:10.1038/s41418-021-00847-3.
PMID: 34389813 - 5
Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management.
Newman NJ, Yu-Wai-Man P, Biousse V, Carelli V
The Lancet. Neurology 2023; (22(2)):172-188 doi:10.1016/S1474-4422(22)00174-0.
PMID: 36155660 - 6
Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies.
Lopez Sanchez MI, Crowston JG, Mackey DA, Trounce IA
Pharmacology & therapeutics 2016; (165()):132-52.
PMID: 27288727 - 7
Severe Optic Neuropathy Induced by Very Prolonged Tedizolid as Suppressive Therapy: Description of a Case Report and Implication for Better Assessment.
Coustilleres F, Thillard EM, Khanna RK, et al.
Open forum infectious diseases 2024; (11(9)):ofae517 doi:10.1093/ofid/ofae517.
PMID: 39329109 - 8
LINEZOLID-INDUCED MITOCHONDRIAL TOXICITY PRESENTING AS RETINAL NERVE FIBER LAYER MICROCYSTS AND OPTIC AND PERIPHERAL NEUROPATHY IN A PATIENT WITH CHRONIC GRANULOMATOUS DISEASE.
Pilania RK, Arora A, Agarwal A, et al.
Retinal cases & brief reports 2021; (15(3)):224-229 doi:10.1097/ICB.0000000000000777.
PMID: 30048406 - 9
Mutation Screening of mtDNA Combined Targeted Exon Sequencing in a Cohort With Suspected Hereditary Optic Neuropathy.
Li JK, Li W, Gao FJ, et al.
Translational vision science & technology 2020; (9(8)):11 doi:10.1167/tvst.9.8.11.
PMID: 32855858 - 10
Mitochondrial optic neuropathies.
Carelli V, La Morgia C, Yu-Wai-Man P
Handbook of clinical neurology 2023; (194()):23-42 doi:10.1016/B978-0-12-821751-1.00010-5.
PMID: 36813316 - 11
Visual Recovery Following Linezolid Cessation in an MDR-TB Patient: Detailed Case Analysis.
Wiyana YB, Marhana IA, Suhartono G, Haryono A
Case reports in pulmonology 2025; (2025()):9939815 doi:10.1155/crpu/9939815.
PMID: 40756245 - 12
The antiretroviral 2',3'-dideoxycytidine causes mitochondrial dysfunction in proliferating and differentiated HepaRG human cell cultures.
Young CKJ, Wheeler JH, Rahman MM, Young MJ
The Journal of biological chemistry 2021; (296()):100206 doi:10.1074/jbc.RA120.014885.
PMID: 33334881 - 13
A comparison of machine learning techniques for classification of HIV patients with antiretroviral therapy-induced mitochondrial toxicity from those without mitochondrial toxicity.
Lee JS, Paintsil E, Gopalakrishnan V, Ghebremichael M
BMC medical research methodology 2019; (19(1)):216 doi:10.1186/s12874-019-0848-z.
PMID: 31775643 - 14
Effect of adenosine triphosphate on amiodarone-induced optic neuropathy in rats: biochemical and histopathological evaluation.
Bayrakçeken K, Ucgul RK, Coban T, et al.
Cutaneous and ocular toxicology 2023; (42(3)):162-167 doi:10.1080/15569527.2023.2227265.
PMID: 37335833 - 15
Oxidative Stress in Optic Neuropathies.
Sanz-Morello B, Ahmadi H, Vohra R, et al.
Antioxidants (Basel, Switzerland) 2021; (10(10)) doi:10.3390/antiox10101538.
PMID: 34679672 - 16
Nationwide usage of ethambutol and incidence and screening practices of optic neuropathy.
Kim J, Kwon HY, Ahn SJ
Frontiers in pharmacology 2024; (15()):1461111 doi:10.3389/fphar.2024.1461111.
PMID: 39474613 - 17
Optic neuritis secondary to antiandrogen therapy.
Ní Mhéalóid Á, Cunniffe G
Irish journal of medical science 2017; (186(3)):565-570 doi:10.1007/s11845-016-1544-1.
PMID: 28039596
This page about medication safety and ADOA is for informational purposes only. Always consult your ophthalmologist or prescribing physician before stopping, starting, or changing any medications.
Get notified when new evidence is published on Autosomal dominant optic atrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.